Novartis Ag - NOVN- Profile

Home » Directory » Pharmaceuticals & Biotechnology » Novartis Ag » Profile

Website: http://www.novartis.com

Phone: +41 61 324 1111
Address:
CH-4002 Basel
4002 Basel,

Company Description
Novartis AG. The Group's principal activity is the development and manufacture of pharmaceuticals and nutritional products. The Group operates through four divisions; Pharmaceuticals, Consumer Health, Sandoz & Vaccines & Diagnostics. Pharmaceuticals Division includes drugs for use in transplantations, central nervous system disorders, cardiovascular, endocrine and respiratory diseases, dermatology, oncology, hematology and rheumatism and bone and hormone replacement therapy. Consumer Health Division includes Generics/OTC and sells copies of prescription medicines no longer under patent protection; medical nutrition and self-medication. Sandoz Division: Manufactures, distributes and sells generic pharmaceutical products and substances no longer subject to patent protection. Vaccines & Diagnostics Division provides innovative vaccines and a range of conventional products to combat viral and bacterial diseases. In 2006, the Group acquired Chiron Corporation & NeuTec Pharma plc. Pharmaceuticals accounted for 63% of 2006 revenues, Consumer Health, 18%, Sandoz, 17% & Vaccines & Diagnostics, 2%
Key People
Chairman, President & Chief Executive Dr. Daniel Vasella
Chief Financial Officer Raymund Breu
Vice Chairman Prof. Ulrich Lehner
Vice Chairman Hans-Joerg Rudloff
Secretary Monika Matti

Related Business Topics
click here
A-Z Novartis Ag Provider Directory
0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
N
Novartis AG
Discovers, develops, manufactures and markets arthritis, inflammation, bone, cardiovascular, metabolic, dermatology, hematology, neuroscience, and oncology drugs.
www.novartis.com
Breaking News
Forbes.com - 3 hours ago
FRANKFURT, July 6 (Reuters) - Morphosys AG: * Says Novartis ( NVS - news - people ) has committed to a ten-year term of the strategic alliance * Says collaboration will now run until 2017 and may be extended by Novartis for an additional two years beyond ...
Reuters India - July 02, 2009 6:48 PM
By Julie Steenhuysen CHICAGO (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday. They said computer models and lab experiments suggest ...
Forbes.com - July 02, 2009 6:45 PM
CHICAGO, July 2 (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday. They said computer models and lab experiments suggest the drugs ...
Reuters UK - July 02, 2009 5:39 PM
By Julie Steenhuysen CHICAGO (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday. They said computer models and lab experiments suggest ...
Reuters - July 02, 2009 5:32 PM
* Drugs could be used to fight dangerous forms of TB * Compounds already proven in humans CHICAGO, July 2 (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. ...
Find Free Prescriptions
Prescription Assistance Programs Annual Income under $42k to Join
www.myrxadvocate.com
Careers at Abbott
Work in a dynamic environment that inspires innovation.
www.AbbottInCalifornia.com
Healthcare Sector Journal
Mergers, Pricing, Innovation & More From Morningstar. Try Risk Free!
Morningstar.com/HealthcareObserver

Overview  |  Profile
What Works for Business Newsletter

Get fresh ideas for managing & growing your business.

Click here to view a sample issue